Together, we can find a cure
all donations are tax deductible
What are Desmoid Tumours?
Desmoid tumours (also known as aggressive fibromatosis, desmoid fibromatosis and desmoid-type fibromatosis) are rare, locally invasive, soft tissue tumours that affect approximately 2-4 people in 1 million every year.
They can occur anywhere in the body and, though they do not metastasize, they can damage surrounding tissues and vital structures as they grow.
Behind the Breakthroughs: The Your Stories Podcast
DTRF Co-Founder, Marlene Portnoy, and DTRF Scientific Director Dr. Mrinal Grounder candidly discuss the joint impact of DTRF's patient advocacy and Dr. Grounder's research that led to the breakthrough clinical trial of sorafenib.
Help Us Do More
Host your own event, create a fundraising campaign or encourage company donations. We’ve got the resources to help you out.
Explore our Updated Physicians Guide
Global Consensus Paper on Treatment
We are pleased to share the publication of the first-of-its-kind Global Consensus Paper on desmoid tumour treatment in the European Journal on Medicine.
Funded in part by our American Colleagues at DTRF, the Global Consensus Paper answers critical questions regarding the approach to treatment recommendations, types of treatment and pain management.
Consensus amongst doctors and scientists is groundbreaking, as treatments, medical therapies and information in general varies by country. Many patients worldwide are treated based on the experience of a single physician, which may be limited.
This collaborative paper will help improve standards for treatment and serves as a powerful resource for patients, caregivers and medical professionals worldwide.
Recent Updates
Recent Posts
-
November 28, 2023 Breaking News FDA Approves OGSIVEO ( nirogacestat)
-
November 29, 2019 PHASE III SORAFENIB DESMOID TUMOR STUDY
Athina's Ride
100% of proceeds raised will be donated to the Desmoid Tumour Foundation of Canada
